



MESCO PHARMACEUTICALS LIMITED

Corporate Identity No. L24111UR1986PLC015895

Corp Off: Mesco Tower, H-1, Zamrudpur Community Centre, Kailash Colony, New Delhi- 110 048

Tel: 011 29241099, 40587083, 40587085, E-mail: mescogroup@rediffmail.com

13th July, 2015

BSE Ltd

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001, Maharashtra

Sub: Submission of Quarterly Corporate Governance Report under Clause 49 as on 30th June, 2015

Dear Sirs

In terms of the provisions of Clause 49 of the Listing Agreement, we are pleased to submit herewith the Quarterly Corporate Governance Report under Clause 49 as on 30th June, 2015.

We hope you will find the above in order.

Yours Sincerely

For Mesco Pharmaceuticals Ltd

For Mesco Pharmaceuticals Ltd.

N.S. Parameswaran
Additional Director

Director

Encl.: a/a

Annexure -XI to the Listing Agreement Format of Quarterly Compliance Report on Corporate Governance

Name of the Company: Mesco Pharmaceuticals Ltd

Quarter ending on: 30th June, 2015

Particulars	Clause of Listing agreement	Compliance Status Yes/No/N.A	Remarks
II. Board of Directors	49 (II)		
(A) Composition of Board	49 (IIA)	No	Company is in the process of appointing Independent Directors
(B) Independent Directors	49 (IIB)	No	Company is in the process of appointing Independent Directors
(C) Non-executive Directors' compensation & disclosures	49 (IIC)	Yes	No remuneration being paid to any non-executive director
(D) Other provisions as to Board and Committees	49 (IID)	No	-
(E) Code of Conduct	49 (IIE)	Yes	-
(F) Whistle Blower Policy	49 (IIF)	Yes	-
III. Audit Committee	49 (III)		
(A) Qualified & Independent Audit Committee	49 (IIIA)	No	Company is in the process of appointing Independent Directors
(B) Meeting of Audit Committee	49 (IIIB)	No	Company is in the process of appointing Independent Directors
(C) Powers of Audit Committee	49 (IIIC)	Yes	-
(D) Role of Audit Committee	49 (IIID)	Yes	-
(E) Review of Information by Audit Committee	49 (IIIE)	Yes	-
IV. Nomination and Remuneration Committee	49 (IV)	No	Company is in the process of appointing Independent Directors
V. Subsidiary Companies	49 (V)	NA	No subsidiary Company
VI. Risk Management	49 (VI)	NA	-
VII. Related Party Transactions	49 (VII)	Yes	-
VIII. Disclosures	49 (VIII)		
(A) Related party transactions	49 (VIII A)	Yes	-
(B) Disclosure of Accounting Treatment	49 (VIII B)	Yes	-
(C) Remuneration of Directors	49 (VIII C)	NA	-
(D) Management	49 (VIII D)	Yes	will be complied in the next Annual Report
(E) Shareholders	49 (VIII E)	Yes	will be complied in the next Annual Report
(F) Proceeds from public issues, rights issue, preferential issues, etc	49 (VIII F)	NA	-
IX. CEO/CFO Certification	49 (IX)	Yes	will be complied in the next Annual Report
X. Report on Corporate Governance	49 (X)	Yes	will be complied in the next Annual Report
XI. Compliance	49 (XI)	Yes	will be complied in the next Annual Report

For Mesco Pharmaceuticals Ltd.

[Signature]

Director